TY - JOUR
T1 - Central and peripheral dopamine transporter reduction in Parkinson's disease
AU - Buttarelli, Francesca R.
AU - Capriotti, Gabriela
AU - Pellicano, Clelia
AU - Prosperi, Daniela
AU - Circella, Annapia
AU - Festa, Anna
AU - Giovannelli, Morena
AU - Tofani, Anna
AU - Pontieri, Francesco E.
AU - Scopinaro, Francesco
PY - 2009/9
Y1 - 2009/9
N2 - Objective: Previous reports showed the reduction of dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. In this work, we sought to investigate the possible correlation between central and peripheral dopamine transporter immunoreactivity values in a group of 11 drug-naive patients with Parkinson's disease. Methods: Densitometric measurements of dopamine transporter immunoreactivity in peripheral blood lymphocytes was accomplished as described recently, using a monoclonal antidopamine transporter antibody. Dopamine transporter binding in the caudate and putamen nuclei was measured by means of 123 I-fluopane single-photon emission computed tomography in the same patients. Results: The results failed to show any significant correlation between dopamine transporter immunoreactivity in peripheral blood lymphocytes and the caudate or putamen dopamine transporter binding. Moreover, dopamine transporter immunoreactivity in peripheral blood lymphocytes was reduced also in the single patient with normal striatal dopamine transporter binding. Discussion: These results indicate the lack of correlation between central and peripheral dopamine transporter reduction in Parkinson's disease, using the methodologies applied herein. They therefore suggest that the two phenomena are unlikely to share a common pathogenetic mechanism.
AB - Objective: Previous reports showed the reduction of dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson's disease. In this work, we sought to investigate the possible correlation between central and peripheral dopamine transporter immunoreactivity values in a group of 11 drug-naive patients with Parkinson's disease. Methods: Densitometric measurements of dopamine transporter immunoreactivity in peripheral blood lymphocytes was accomplished as described recently, using a monoclonal antidopamine transporter antibody. Dopamine transporter binding in the caudate and putamen nuclei was measured by means of 123 I-fluopane single-photon emission computed tomography in the same patients. Results: The results failed to show any significant correlation between dopamine transporter immunoreactivity in peripheral blood lymphocytes and the caudate or putamen dopamine transporter binding. Moreover, dopamine transporter immunoreactivity in peripheral blood lymphocytes was reduced also in the single patient with normal striatal dopamine transporter binding. Discussion: These results indicate the lack of correlation between central and peripheral dopamine transporter reduction in Parkinson's disease, using the methodologies applied herein. They therefore suggest that the two phenomena are unlikely to share a common pathogenetic mechanism.
KW - Dopamine transporter
KW - Immunocytochemistry
KW - Parkinson's disease
KW - Peripheral blood lymphocytes
KW - Single-photon emission computed tomography
UR - http://www.scopus.com/inward/record.url?scp=68849106535&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68849106535&partnerID=8YFLogxK
U2 - 10.1179/174313209X383259
DO - 10.1179/174313209X383259
M3 - Article
C2 - 19061540
AN - SCOPUS:68849106535
VL - 31
SP - 687
EP - 691
JO - Neurological Research
JF - Neurological Research
SN - 0161-6412
IS - 7
ER -